{"type":"trials","record":{"id":41527,"source_id":"clinicaltrials-gov","external_id":"NCT05803785","title":"Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)","brief_summary":"This open-label study is being conducted to evaluate the initial safety and tolerability of BBC1501 IVT in patients with nAMD. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of IVT BBC1501 in patients with nAMD. The secondary objective of this study is to exploratory of BBC1501 efficacy following 3 ascending dose of BBC1501 in nAMD patient.","overall_status":"Recruiting","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"Benobio Co., Ltd.","enrollment":18,"countries":["Australia"],"start_date":"2025-07-01","completion_date":"2026-12-01","last_update_date":"2026-05-15","source_url":"https://clinicaltrials.gov/study/NCT05803785","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Benobio Co., Ltd.","interventions":["BBC1501"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Assessment of ophthalmic and systemic TEAEs, during study period — Every week up to 4 weeks","Assessment of ophthalmic and systemic TEAEs, during study period — every 4 weeks up to 12 weeks","Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA from baseline — Baseline, Week4","Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA from baseline — Baseline, Week12","Number of patients who initiation of rescue therapy during study — Week1, Week12"],"design_description":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration","BBC1501"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05803785","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-07-01 to 2026-12-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.828Z","intervention":["BBC1501"],"participants":18,"study_design":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Assessment of ophthalmic and systemic TEAEs, during study period — Every week up to 4 weeks","Assessment of ophthalmic and systemic TEAEs, during study period — every 4 weeks up to 12 weeks","Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA from baseline — Baseline, Week4","Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA from baseline — Baseline, Week12","Number of patients who initiation of rescue therapy during study — Week1, Week12"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41527","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}